Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a poly…
Sponsor: NRG Oncology
NCT ID: NCT06580314
Sites in Montana: - Community Hospital of Anaconda — Anaconda, Montana
- Billings Clinic Cancer Center — Billings, Montana
- Saint Vincent Healthcare — Billings, Montana
- Saint Vincent Frontier Cancer Center — Billings, Montana
- Intermountain Health West End Clinic — Billings, Montana
Phase 3 Recruiting Industry
The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.
Sponsor: Incyte Corporation
NCT ID: NCT07214779
Sites in Montana: - Billings Clinic — Billings, Montana
Phase 3 Recruiting Industry
This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expr…
Sponsor: Daiichi Sankyo
NCT ID: NCT06819007
Sites in Montana: - St. Vincent Gynecologic Oncology — Billings, Montana
Phase 3 Recruiting Industry
This study will evaluate the efficacy, safety and tolerability of Torvutatug samrotecan (torvu-sam) in combination with bevacizumab compared with bevacizumab monotherapy as first line maintenance treatment in patients with non-Homologous R…
Sponsor: AstraZeneca
NCT ID: NCT07851025
Sites in Montana: - Research Site — Billings, Montana
Phase 2 Recruiting NIH
This phase II trial tests whether the combination of nivolumab and ipilimumab is better than nivolumab alone to shrink tumors in patients with deficient mismatch repair system (dMMR) endometrial carcinoma that has come back after a period …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05112601
Sites in Montana: - Community Hospital of Anaconda — Anaconda, Montana
- Billings Clinic Cancer Center — Billings, Montana
- Saint Vincent Frontier Cancer Center — Billings, Montana
- Intermountain Health West End Clinic — Billings, Montana
- Bozeman Health Deaconess Hospital — Bozeman, Montana
Phase 2 Recruiting Industry
This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression.
Sponsor: Incyte Corporation
NCT ID: NCT07023627
Sites in Montana: - St. Vincent Regional Hospital - West End Clinic — Billings, Montana
Phase 2 Recruiting Industry
Ovarian cancer is a lethal disease with an estimated 310,000 new cases and 200,000 deaths experienced worldwide in 2020. The purpose of this study is to assess the adverse events and change in disease activity of mirvetuximab soravtansine …
Sponsor: AbbVie
NCT ID: NCT07059845
Sites in Montana: - Intermountain Health - Intermountain Health West End Clinic /ID# 278470 — Billings, Montana
Phase 2 Recruiting NIH
This phase II trial compares the effect of sacituzumab govitecan and bevacizumab to standard care (carboplatin, pegylated liposomal doxorubicin, and bevacizumab) in patients with ovarian cancer that has come back after an initial response …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07504588
Sites in Montana: - Community Hospital of Anaconda — Anaconda, Montana
- Billings Clinic Cancer Center — Billings, Montana
- Benefis Sletten Cancer Institute — Great Falls, Montana
- Logan Health Medical Center — Kalispell, Montana
- Community Medical Center — Missoula, Montana
Phase 1 Recruiting Industry
The primary objective of this trial is to evaluate ovarian suppression following treatment with ZOLADEX 10.8 mg by luteinizing hormone (LH) within each cohort.
Sponsor: TerSera Therapeutics LLC
NCT ID: NCT07310420
Sites in Montana: - St. Vincent Frontier Cancer Center (SVFCC) - Billings (Frontier Cancer Center and Blood Institute) — Billings, Montana
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Montana: - Community Hospital of Anaconda — Anaconda, Montana
- Billings Clinic Cancer Center — Billings, Montana
- Bozeman Health Deaconess Hospital — Bozeman, Montana
- Benefis Sletten Cancer Institute — Great Falls, Montana
- Great Falls Clinic — Great Falls, Montana
NA Recruiting Academic/Other
This clinical trial evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves…
Sponsor: NRG Oncology
NCT ID: NCT04251052
Sites in Montana: - Billings Clinic Cancer Center — Billings, Montana
- Saint Vincent Healthcare — Billings, Montana
- Saint Vincent Frontier Cancer Center — Billings, Montana
- Intermountain Health West End Clinic — Billings, Montana
- Bozeman Health Deaconess Hospital — Bozeman, Montana
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Montana: - Massive Bio SYNERGY-AI site — Billings, Montana
Recruiting Academic/Other
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, h…
Sponsor: University of Nebraska
NCT ID: NCT02012699
Sites in Montana: - Bozeman Health Deaconess Hospital — Bozeman, Montana